Three posters related to the Company’s proprietary ADC technology will be presented at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 14 to 18, 2018, in Chicago, Illinois:
April 15, 2018, 1:00 PM-5:00 PM in Section 35
ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors
Link to Abstract
April 16, 2018, 1:00 PM-5:00 PM in Section 34
Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors
Link to Abstract
April 17, 2018, 8:00 AM-12:00 PM in Section 34
Decomposition of parameters contributing to the improved therapeutic index of ADCs obtained by GlycoConnect™ and HydraSpace™ Technologies
Link to Abstract
